Blincyto
Blinatumomab · Bispecific T-Cell Engager (BiTE) Antibody
Indications & Uses
Relapsed/refractory Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Small Cell Lung Cancer, or Acute Lymphoblastic Leukemia.
Contraindications
Hypersensitivity to active ingredient or any formulation excipients.
Side Effects & Warnings
Cytokine release syndrome (CRS), neurologic toxicity, severe infections, cytopenias, musculoskeletal pain.
Drug & Dietary Interactions
Caution with strong CYP3A inhibitors or inducers; review concurrent medications.
For educational and informational purposes only. Do not alter medication doses or regimens without consulting your licensed oncology physician or care team.
Patient & Caregiver Support
Ask About This Medication
Connect with an ONC-ORG counselor regarding drug access, copay relief, patient assistance programs, or related clinical trials.